NCT03290079 2025-12-22Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine TumorsH. Lee Moffitt Cancer Center and Research InstitutePhase 2 Completed20 enrolled 12 charts
NCT02678780 2025-07-24TALENTGrupo Espanol de Tumores NeuroendocrinosPhase 2 Completed123 enrolled 37 charts